Stockscreener 앱 받기
1.01
3.58%
0.0349
전일 마감가:
$0.9751
열려 있는:
$0.966
하루 거래량:
109.61K
Relative Volume:
0.44
시가총액:
$24.17M
수익:
-
순이익/손실:
$-21.54M
주가수익비율:
-1.0198
EPS:
-0.9904
순현금흐름:
$-19.60M
1주 성능:
-8.60%
1개월 성능:
-41.62%
6개월 성능:
-76.67%
1년 성능:
-87.71%
1일 변동 폭
$0.90
$1.03
1주일 범위
$0.90
$1.14
52주 변동 폭
$0.90
$9.22
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
1.01 | 23.21M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-26 | 개시 | B. Riley Securities | Buy |
| 2025-04-22 | 개시 | Craig Hallum | Buy |
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - tradingkey.com
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.170|Chg%:-0.010 - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.185|Chg%:-0.075 - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics Q1 2026 Earnings: EPS Miss and Pre-Revenue Status Weigh on StockGAAP Earnings Report - dars.gov.et
Actuate Therapeutics Inc. (ACTU) Q1 2026 Earnings: EPS Miss of 8.6% Reflects Continued Pre-Revenue Investment PhasePerformance Review - dars.gov.et
Actuate Therapeutics, Inc. Files Form 8-K: NASDAQ Compliance Update and Company Details (July 2026) - Minichart
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Actuate Therapeutics (ACTU) Surges 17.8% as Momentum Builds After Support TestgetLinesFromResByArray error: size == 0 - dars.gov.et
ACTU Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock RallyDividend Growth Analysis - dars.gov.et
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Price to book forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to sales forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Number of shareholders of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to earnings forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Actuate Therapeutics (ACTU) Declines Sharply – Key Support Tested at $1.73Double Top - dars.gov.et
Actuate Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACTU) - TradingView
ACTU Forecast — Price Target — Prediction for 2027 - tradingview.com
Actuate Therapeutics (ACTU) Finds Its Footing Near Key Support After a Modest GainEarnings Beat Stocks - dars.gov.et
Actuate Therapeutics (ACTU) Holds Near Key Support After Modest GainIV Crush Alert - dars.gov.et
Actuate Therapeutics (ACTU) Gains 2.8% on Elevated Volume, Tests Key Resistance at $2.19Single Stock ETF - DonanımHaber
Actuate Therapeutics Inc (ACTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):